I can’t stand all these bugs coming out of the woodwork to bash our stock. Shingel, RDB, etc. Why is this PR being slammed? We reduced death by 24%. If I was on a ventilator, You better believe I’m asking for VX. It can also get people out of the hospital 6 days quicker to open up more beds. No iv necessary and a superb health record. The FDA has no worries about offering this as an EUA. Remdesivir showed almost no clinical benefit, it got eua. Plasma- almost no benefit- it got EUA. I think the FDA needs to approve or EUA a therapy that actually does help. How far off were we from missing our primary endpoint? Where is the rest of our data?